Wei‐Chun Hsu

645 total citations · 1 hit paper
15 papers, 424 citations indexed

About

Wei‐Chun Hsu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Wei‐Chun Hsu has authored 15 papers receiving a total of 424 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 4 papers in Surgery. Recurrent topics in Wei‐Chun Hsu's work include Advanced Breast Cancer Therapies (3 papers), Cancer Treatment and Pharmacology (3 papers) and CAR-T cell therapy research (2 papers). Wei‐Chun Hsu is often cited by papers focused on Advanced Breast Cancer Therapies (3 papers), Cancer Treatment and Pharmacology (3 papers) and CAR-T cell therapy research (2 papers). Wei‐Chun Hsu collaborates with scholars based in United States, France and Switzerland. Wei‐Chun Hsu's co-authors include Hemanth Kanakamedala, Jialin Mao, Art Sedrakyan, Stephen Chia, Stuart Turner, Hope S. Rugo, Juan Pablo Zarate, Patrick Neven, Dejan Juric and Eva Ciruelos and has published in prestigious journals such as Blood, Cancer and The Lancet Oncology.

In The Last Decade

Wei‐Chun Hsu

13 papers receiving 417 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

2021 223 citations Hope S. Rugo, Florence Lerebours et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wei‐Chun Hsu United States	8	242	175	97	95	60	15	424
Taher Abu Hejleh United States	11	158 0.7×	254 1.5×	67 0.7×	121 1.3×	17 0.3×	45	445
László Thurzó Hungary	14	131 0.5×	213 1.2×	228 2.4×	110 1.2×	13 0.2×	45	613
L. Brureau France	15	342 1.4×	102 0.6×	99 1.0×	104 1.1×	19 0.3×	55	535
Sophie Dussart France	11	128 0.5×	78 0.4×	18 0.2×	73 0.8×	47 0.8×	24	312
Duc Le Canada	10	97 0.4×	153 0.9×	37 0.4×	67 0.7×	38 0.6×	26	308
A. Wygoda Poland	13	301 1.2×	180 1.0×	137 1.4×	142 1.5×	11 0.2×	55	664
Simin Sadeghi‐Bojd Iran	13	108 0.4×	40 0.2×	118 1.2×	117 1.2×	84 1.4×	61	486
Samuel Tekyi‐Mensah United States	10	216 0.9×	52 0.3×	68 0.7×	45 0.5×	51 0.8×	16	449
Henk Codrington Netherlands	11	439 1.8×	236 1.3×	33 0.3×	59 0.6×	23 0.4×	20	587
Neeta K. Venepalli United States	11	63 0.3×	84 0.5×	55 0.6×	64 0.7×	16 0.3×	33	434

Countries citing papers authored by Wei‐Chun Hsu

Since Specialization

Citations

This map shows the geographic impact of Wei‐Chun Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei‐Chun Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei‐Chun Hsu more than expected).

Fields of papers citing papers by Wei‐Chun Hsu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wei‐Chun Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei‐Chun Hsu. The network helps show where Wei‐Chun Hsu may publish in the future.

Co-authorship network of co-authors of Wei‐Chun Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Wei‐Chun Hsu. A scholar is included among the top collaborators of Wei‐Chun Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wei‐Chun Hsu. Wei‐Chun Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Hsu, Wei‐Chun, Aaron Crowley, & Craig S. Parzynski. (2024). The impact of different censoring methods for analyzing survival using real-world data with linked mortality information: a simulation study. BMC Medical Research Methodology. 24(1). 203–203. 1 indexed citations

Hsu, Wei‐Chun, Chien‐Ming Chen, Chia‐Jung Kuo, et al.. (2024). Upper Gastrointestinal Involvement in Crohn’s Disease as an Independent Predictor of New-Onset Strictures: Insights from an Extensive Retrospective Cohort Analysis. Digestive Diseases and Sciences. 69(9). 3382–3391.

Rugo, Hope S., Florence Lerebours, Eva Ciruelos, et al.. (2024). Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. The Lancet Oncology. 25(12). e629–e638. 10 indexed citations

Hao, Yanni, Wei‐Chun Hsu, Craig S. Parzynski, et al.. (2023). Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma. Journal of Comparative Effectiveness Research. 12(7). e220173–e220173. 3 indexed citations

Hampson, Lisa V., Jufen Chu, Aiesha Zia, et al.. (2023). Combining the Target Trial and Estimand Frameworks to Define the Causal Estimand: An Application Using Real-World Data to Contextualize a Single-Arm Trial. Statistics in Biopharmaceutical Research. 16(1). 1–10. 5 indexed citations

Pan, Hongming, Yuxian Bai, Ying Cheng, et al.. (2022). [Atezolizumab therapy in Chinese patients with locally advanced or metastatic solid tumors: An open-label, phase Ⅰ study].. PubMed. 54(5). 971–980. 1 indexed citations

Turner, Stuart, Stephen Chia, Hemanth Kanakamedala, et al.. (2021). Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2–, PIK3CA-Mutated Breast Cancer. The Oncologist. 26(7). e1133–e1142. 23 indexed citations

Rugo, Hope S., Florence Lerebours, Eva Ciruelos, et al.. (2021). Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. The Lancet Oncology. 22(4). 489–498. 223 indexed citations breakdown →

Hao, Yanni, Wei‐Chun Hsu, Craig S. Parzynski, et al.. (2021). Comparison of Clinical Outcomes Among Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel in the Elara Trial Versus a Real-World External Control Arm of Patients Treated with Standard of Care. Blood. 138(Supplement 1). 2419–2419. 2 indexed citations

10.

Lodise, Thomas P., Hemanth Kanakamedala, Wei‐Chun Hsu, & Bin Cai. (2020). Impact of Incremental Delays in Appropriate Therapy on the Outcomes of Hospitalized Adult Patients with Gram‐negative Bloodstream Infections: “Every day matters”. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 40(9). 889–901. 14 indexed citations

11.

Ramakrishna, Rohan, Wei‐Chun Hsu, Jialin Mao, & Art Sedrakyan. (2018). Surgeon Annual and Cumulative Volumes Predict Early Postoperative Outcomes After Brain Tumor Resection. World Neurosurgery. 114. e254–e266. 18 indexed citations

12.

Baaj, Ali A., Gernot Lang, Wei‐Chun Hsu, et al.. (2017). 90-day Readmission After Lumbar Spinal Fusion Surgery in New York State Between 2005 and 2014. Spine. 42(22). 1706–1716. 36 indexed citations

13.

Shoag, Jonathan E., Art Sedrakyan, Joshua A. Halpern, Wei‐Chun Hsu, & Jim C. Hu. (2017). MP14-15 INCREASE IN THE INCIDENCE OF ADVANCED PROSTATE CANCER IN THE UNITED STATES. The Journal of Urology. 197(4S). 1 indexed citations

14.

Ladas, Elena J., et al.. (2017). Predictors of acupuncture use among children and adolescents with cancer. Pediatric Blood & Cancer. 64(7). e26424–e26424. 27 indexed citations

15.

Halpern, Joshua A., Art Sedrakyan, Wei‐Chun Hsu, et al.. (2016). Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer. Cancer. 122(16). 2496–2504. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact